Overview

Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy

Status:
No longer available

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This expanded access study is designed to provide RAD001 to patients with MRCC who are without satisfactory treatment alternatives, until RAD001 becomes commercially available.

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Endothelial Growth Factors
Everolimus
Mitogens